

Dynamic and results-oriented pharmaceutical leader with over 14 years of experience across Biogen, Boehringer Ingelheim, and Janssen, driving growth and excellence in rare diseases, neuroscience, and immunology across the GCC region.
Proven success in leading commercial strategy, launches, and cross-functional operations for breakthrough therapies including Spinraza (SMA) and Skyclarys (FA).
Recognized for building high-impact partnerships, executing data-driven initiatives, and advancing patient access through innovation and collaboration.
Responsible for shape, lead, and execute e the brand strategy of Tremfya and Stelara in Psoriatic Arthritis across the GCC